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Two decades since their inception, multidisciplinary teams (MDTs) are widely regarded as the ‘gold standard’ of cancer care
delivery. Benefits of MDT working include improved patient outcomes, adherence to guidelines, and even economic
benefits. Benefits to MDT members have also been demonstrated. An increasing body of evidence supports the use of
MDTs and provides guidance on best practise. The system of MDTs in cancer care has come under increasing pressure of
late, due to the increasing incidence of cancer, the popularity of MDT working, and financial pressures. This pressure has
resulted in recommendations by national bodies to implement streamlining to reduce workload and improve efficiency. In
the present review we examine the historical evidence for MDT working, and the scientific developments that dictate best
practise. We also explore how streamlining can be safely and effectively undertaken. Finally, we discuss the future of MDT
working including the integration of artificial intelligence and decision support systems and propose a new model for
improving patient centredness.
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Why do we have multidisciplinary teams?
Multidisciplinary teams (MDTs) are widely regarded as the
‘gold standard’ of cancer care delivery. The concept of MDT
working was introduced >20 years ago to address
discrepancies in the quality of care and improve the timely
coordination and delivery of care. Since then, the practice of
MDT working has been adopted by many countries
worldwide. Presentation of cancer cases at MDT meetings
(MDTMs) is recommended by a number of professional
bodies and international guidelines [1, 2].
The MDT generally consists of histopathologists, radiologists,
surgeons, cancer nurse specialists, oncologists, and
administrators, also known as MDT coordinators. Depending
on tumour type, there may be other members such as chest
physicians, haematologists, or allied health professionals.
Central to MDT working is the MDTM, where cases are
presented, information shared and reviewed, and care
management discussed and documented. MDTMs typically
occur weekly or fortnightly and can last several hours, with
discussion of as many as, on average, 50 cases. The decision-
making process in MDTMs should be driven by and is
dependent on a combination of holistic and clinical inputs,
including the patient history, comorbidities, psychosocial
information, patient views on treatment options (if available
at the point of the MDTM), pathology, and radiology, along
with effective MDTM management [3].
Consistent with the objectives of multidisciplinary care at its
inception, demonstrated benefits include improved adherence
to best clinical practice, improved timeliness of diagnostics
and treatment, and improved patient outcomes, including
survival [4, 5]. In addition, other benefits that have become
apparent include improved healthcare professional wellbeing,
education, and quality assurance [6]. Moreover, the roles of
healthcare professionals, e.g. pathologists and radiologists,
have become embedded in and integral to the care
pathway. The cost-effectiveness of MDT working remains
contentious, but evidence is emerging of the financial
benefits of MDTs through improvements in the
organisation and delivery of care [7]. MDT working is
strongly supported by the urological community and is
regarded as a driver of improved quality of care. Following
success of the MDT model in cancer care, it has now been
extended to the management of benign diseases that involve
complex care [8]. For instance, MDT working in urology is
applied in some NHS Trusts to conditions such as stone
management, urinary incontinence, reconstructive urology,
and andrology [9].
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What makes an MDT Meeting Effective?
Over the past decade, key performance indicators have been
generated through research and stakeholder engagement, with
high levels of agreement between different cancer teams in
terms of what constitutes effective MDT working [10].
Improvement research focussed on cancer MDTs over the
past 10 years, mostly in the UK, has provided a ‘tool kit’ with
which MDT members can assure and improve the quality of
their MDTs. Over this period, research into the workings of
cancer MDTs has been undertaken, and an evidence base has
been accumulated on the factors that promote or hinder
teams to review patients holistically within a MDTM, and
make recommendations that are both clinically sound and
acceptable to patients [11].
Several evidence-based tools for the assessment and
improvement of the performance of MDTs (Table 1; [11–19])
have been developed. These tools can be used by clinicians,
administrators, or researchers to gain an objective
understanding of how their teams are performing. They can
be used as part of an audit or quality improvement initiative
to improve the delivery of care for patients, and as an aid to
streamlining MDTMs. Of particular relevance at present is an
evidence-based stakeholder-driven algorithm (Measure of
case-Discussion Complexity [MeDiC]) to aid streamlining of
MDTMs through patient selection according to specific
complexity indicators [20]; this is in line with the most recent
initiative by the NHS England and NHS Improvement [21].
These tools can be applied at different points along the MDT
pathway: for pre-MDTM case selection; for intra-MDTM
streamlining; and post-MDTM, for team reflection,
assessment and team building (Fig. 1; 23).
Challenges to MDT Meeting Effectiveness
Despite agreement in evidence and opinion on what
constitutes MDT meeting effectiveness, variability remains in
the functioning of MDTs. For example, in the UK, the
Getting It Right Frist Time (GIRFT) Programme National
Speciality Report for Urology found that there is variability
between NHS Trusts in regard to treatment recommendations
by MDTs including, in the proportion of patients who
undergo radical prostatectomy for prostate cancer, or partial
nephrectomy for renal cancer, even accounting for case mix
[9]. Such variation in management, if not explained by
demographic differences, suggests that some MDTs are not
performing optimally.
It is clear from the literature that inefficiencies in existing
MDT processes are commonplace [6]. For example, failure of
clinicians to submit adequate information at the point of
referral means cases are rejected by the MDT and need to be
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recommendations cannot be decided upon; cases with MDT
recommendations that are clinically inappropriate or
unacceptable to patients cannot be implemented. At each of
these junctions, delays in patient care and waste of specialist
staff’s time occur with repeated listing for MDTM,
consuming additional resources. Such inefficiencies arise from
lack of understanding of what is required for effective clinical
decision-making in MDTMs. A number of factors were found
to have an adverse impact on effective clinical decision-
making [11, 22–24]; these include professional hierarchies,
lack of open discussion, failure to consider holistic
information or patient views, lack of personal knowledge of
the patient being discussed, as well as the logistical issues
(administrative, process, attendance, and equipment issues),
time and workload pressures, fatigue, gender imbalance on
the team, and communication practices such as antagonism,
tension and un-acknowledgment of other team members
contributions. Where MDT working has been studied in
detail, these themes have been found to some degree across
all tumour types and all locations.
The difficulty MDTs have in achieving their potential is not
the fault of the healthcare professionals who work hard for
their patients and colleagues, but may instead be a limitation
of the system in which we work. MDTs have become
burdened by increasing workloads with an unmatched,
limited increase in resources to support such work [25–29].
The result is that support services, such as radiology and
pathology cannot meet their MDT commitments whilst
supporting other essential non-MDT related work. The
reasons for growing workload are numerous, including
increased cancer incidence, cancer survival, comorbidities,
population size, and longevity [11, 25–29]. In addition,
perhaps due to the success of the MDT model, many
straightforward or non-cancerous cases are put through the
MDT meeting [30]. It appears that healthcare professionals
appreciate the benefits of the MDT and feel confident in the
safety net it provides for a range of cases, although there are
growing concerns that clinicians now fear making clinical
decisions without the approval of the MDT [31].
Evolution of the MDT Model
Recently, there has been a recognition that the current model
of MDT working, as is mandated in the UK, needs to evolve.
It has been recognised that the concept of reviewing every
new cancer case of suspected or confirmed cancer, as well as
some cases of recurrence, is not sustainable. A national UK
report by Cancer Research UK into the challenges facing
cancer MDTs highlighted the discrepancy between the
demands placed on, and the resources available to MDTs,
while making a number of recommendations for
improvement [32, 33]. Subsequently, the UK Government
Department of Health and Social Care commissioned a
national pilot aimed at transforming the working of cancer
MDTs to increase efficiency in the light of the growing
service demands [31]. With the guidance on streamlining
published by NHS England and NHS Improvement in early
2020, the mandate for discussing all cancer cases no longer
exists in the UK [21].
Focus on Complex Cases
The greatest benefit of MDT working is seen in complex
cases, e.g. unusual subtype of disease, failure of previous
treatment, significant comorbidities, social or psychological
problems. Indeed, evidence shows that the complex cases
yield better quality decision-making and wider contributions

























Tools for continuous MDT self-
reflection & team building:
MDT ATLAS: assessed MDT chairing &
leadership skills; identified areas for
team leadership skills development
MDT FIT: allows holistic team
assessment & reflection and facilitates
team building
MDT-MODe: assesses specialist
contributions to each patient review;
identifies areas that tend to get
neglected and/or professional groups
that tend to not speak up at meetings
MDT meeting
Fig. 1 Diagram representing systems model of input, pathway, output approach for improving cancer care. ATLAS, leadership assessment instrument;
FIT, Feedback for Improving Team Working; MODe, metric of decision-making; QuIC, Quality Improvement Checklist. Reprinted with permission from
https://pubmed.ncbi.nlm.nih.gov/32239992/
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Complexity relating to cases discussed in an MDTM has been
scientifically defined as involving patient factors (socio-
economic, psychological comorbidity, patient preferences),
disease factors (tumour type, stage, grade) and treatment
factors (specialist input, toxicity, monitoring, follow-up, trials,
conflicting data, application of guidelines) [20]. Indicators of
case complexity have been found to be consistent across a
range of tumour types [20]. These patients often do not fit
guidelines, are not eligible for clinical trials, can be
challenging to engage in healthcare services, and may require
tailored individualised treatment plans. Although they
represent a small portion of cases, a considerable amount of
additional support is needed before and after diagnosis and
treatment [34].
Most cases discussed in MDTMs are at the point of
diagnosis, or treatment initiation, and most MDTMs are
chaired by surgeons, with oncologists being less inclined to
refer cases of more advanced disease [35]. However, the MDT
is the ideal forum for making recommendations about
changing treatment strategies for patients with advanced
disease on systemic therapy both in terms of clinical- and
cost-effectiveness [4, 5, 7]. Patients with advanced disease on
systemic therapy are complex for various reasons. For
instance, as a patient’s disease progresses, their performance
status may decline and the toxicity of systemic treatment
increases, the potential benefits of coordinated, holistic MDT
working become more apparent. Furthermore, systemic
treatments, in particular immune therapies, carry a significant
risk of toxicity. Immune-related adverse events are
commonplace and can affect any organ. Accordingly, MDTs
can provide substantial added value in managing immune-
related adverse events and educating healthcare providers
about them [36]. In addition, novel agents for treating
advanced cancer are generally expensive. Weighing up the
benefits and risks of these agents, with limited resources,
treatment recommendations should be made carefully under
the governance structures that exist in the MDT. Indeed,
MDT working has been shown to increase cost-effectiveness
[7]. As the complexity and cost of the management of
advanced disease increases, the MDT approach becomes both
necessary and desirable for these patients and healthcare
professionals alike.
Streamlining MDT Working: Case Selection
for MDT Presentation
It has been proposed that only complex patients, requiring
true multidisciplinary input, would be discussed at MDTMs,
whilst patients not meeting criteria for full discussion would
be treated according to predetermined/agreed algorithms/
guidelines [20, 21, 37]. This would reduce the time all MDT
members, especially radiologists and pathologists, spent in
MDTMs and actually increase the time such complex patients
require for review, which is currently pressurised by the large
volumes of simpler cases that are also mandatorily presented
at the MDTM (such that urological MDTMs have been
shown to spend a median 2–3 min per case discussion,
hardly enough for a complex patient [38]). Evidence to
support this initiative has been provided by several studies
across different tumour types, which have reported reduced
number of cases discussed at MDTMs and a reduction in
MDTM duration. Two national surveys distributed by Cancer
Research UK have shown that 87% of urologists agree that
some patients could be managed outside of full MDT
discussion [39]. Streamlining has be trialled in Urology across
a number of NHS Trusts in the UK, with benefits becoming
apparent [21, 31, 33]. For example, at Southport and
Ormskirk cases were triaged and 15% not discussed that
resulted in a reduction in MDTM duration of ~10 min [9].
This time saving could then be allocated to patients who truly
benefit from a multidisciplinary approach, i.e. complex cases.
NHS England guidance marked a formal endorsement of
streamlining cancer MDTMs in the UK [21]. It may be
desirable therefore to scientifically identify cases that are truly
‘complex’ and those that are ‘simple’ using available tools to
for stratifying cases by complexity (e.g. the MeDiC tool; [20]).
There are concerns that patients not discussed at the MDT
might receive suboptimal care compared to those being
discussed. Given the paucity of regular and rigorous audit of
MDT outcomes, these concerns should be taken seriously.
There is an urgent need to take a scientific approach to
streamlining MDT working, whilst at the same time
maintaining patient safety and the quality of care. Failure to
use best evidence to streamline MDT processes risks reducing
workload at the expense of a return to unwarranted variation
in patient care, as was the case before the introduction of
MDTs in the UK [37, 40]. If this is to be avoided, a
comprehensive approach will be needed (Box 1 [37]).
The careful, planned collection of clinical and process data
is critical to assess and inform complex areas of healthcare
such as care pathways and organisational changes. The
recent NHS England and NHS Improvement report has
highlighted that data collection and regular audit must
accompany MDT transformation [21]. The collection and
analysis of such data might provide a resource to
benchmark processes and outcomes, thereby driving
standardisation and convergence towards best practice [34].
Well-designed data collection supports quality improvement
and clinical research, driving the development of new and
better standards of care.
The time between MDTMs can present a period of
significant stress and anxiety for patients with rapidly
progressing disease waiting for MDT review and
recommendations [34]. In such cases, the MDT Chair is
well placed to endorse management proposals of clinicians
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out with the MDTM in order to avoid delays [34]. Such
cases should still be registered with the MDT and could be
reviewed post hoc. In order to enable the MDT Chair to
assume an enhanced role, in particular as part of
streamlining, triaging cases prior to the MDTM, and using
the Chair’s action for urgent management, the role needs
strengthening. It is important, therefore, that the role has
credibility, which could be enhanced by introducing
competitive application, and also the necessary resources, by
allocating increased time in the job planning for the MDT
Chair. Administrative support for the MDT Chair would
also need to be enhanced by increasing support and training
for MDT coordinators, a professional group critical to
effective MDT function, but historically with little training,
low retention rates, and currently no professional
representation at a national level [41].
The Future Role of Technology in MDT
Working
Computerised Clinical Decision Support Systems
As the complexity of cancer care increases, consideration
must be given to genomic and molecular information, novel
treatments and clinical trials in order to provide patients with
precise and high-quality care. Computerised clinical decision-
support systems (CDSSs) have been developed to support the
quality of care and improve decision-making. At one level,
CDSSs capture patient data and identify eligible patients for
clinical trials, and suggests evidence-based treatment
recommendations [42]. Others may have additional
functionality, such as those that can be integrated into
electronic medical record (EMR) systems and harness
artificial intelligence (AI); with the most advanced being
cognitive computing systems that store and index current
literature, protocols, and patient charts, learning from cases
and improving the performance of the MDT [43–45]. Such
systems have demonstrated improvements on process
outcomes, such as preparation time and guideline adherence
across a number of settings in oncology, including MDTMs.
To date, no improvements in clinical outcomes have bene
demonstrated [46]. Physicians appear to regard CDSSs
favourably, with easy access to well-structured data, and
reducing the time spent by clinicians on MDTM preparation
and duration being desirable features [47]. However, concerns
include incomplete or untrustworthy output generated by the
system and insufficient adaptability of the system to local and
contextual needs [47]. Going forward, CDSSs need further
validation against improved clinical outcomes and
demonstration of flexibility with application to local
healthcare settings [47]. CDSSs have huge potential to
improve the consistency of MDT management
recommendations and their convergence with guidelines by
assisting with the collation of all relevant information for case
discussion, highlighting the current evidence base, and
providing data on previous management decisions for similar
cases. They also offer potential for personalisation of
treatment plans with the integration of molecular medicine,
genetics and clinical trials, including those beyond the
immediate network.
Artificial Intelligence and Machine Learning
Radiologists and pathologists spend significant amounts of
time preparing for MDTMs, far in excess of other members
of the MDTMs [48]. Whilst endeavours to streamline
MDTMs are admirable, they may in fact put more pressure
on histopathology and radiology services by demanding
further preparation in advance of any triaging activity. The
use of AI and machine learning (ML) in these two fields
presents a great opportunity to reduce the workload of
clinicians by accelerating the process of distinguishing
investigations that show benign from malignant disease, as
well as improving risk stratification.
Radiology
Convolutional neural network (CNN) algorithms have been
applied to improve intra- and interobserver discrepancy in
the Prostate Imaging-Reporting and Data System (PI-RADS)
scoring from patients who underwent MRIs for suspicion of
prostate cancer [49]. Other models have incorporated MRI
Box 1 Steps for assuring the quality of the streamlining process
1. All referred cases must be registered with the MDT.
2. Provision of a comprehensive dataset at the point of referral.
3. Case preparation prior to MDTMs by clinical teams (radiology, histopathology
and speciality team).
4. The method of selecting cases for MDT discussion, as well as the standards of
care for patients not being discussed must be robust, coherent, and evidence-based.
5. Strengthening the role of the MDT Lead/Chair with competitive application and
allocated time in the job plan; and also of the MDT coordinator with enhanced
training and support to develop their role to allow them both to effectively
execute and oversee the triage process.
6. Regular and frequent audit of the selection criteria, Standards of Care and patient
outcomes must be undertaken, and the MDT must have the ability to modify
them accordingly in light of the findings.
7. A maximum limit should be set on the number of cases discussed at a single
MDTM.
8. A mandatory short break during the MDTM.
9. Better preparation is needed to smooth out logistical issues ahead of MDTMs,
such as by using a checklist to ensure all the information is readily available
at the MDTM.
10. An MDTM Chair who does not contribute to the clinical discussion could help
the team effectively navigate through workload by reducing tensions, steering
interaction and communication, and ensuring a more uniform decision-making
process for all patients reviewed.
11. Staff selection for MDTs should factor in gender.
© 2021 The Authors
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radiomics data with Gleason scores to train a ML model to
predict clinically significant prostate cancer on MRI images
with some success [50]. In renal cancer, ML models have
been developed to accurately differentiate benign
oncocytomas from RCC [51, 52]. Similarly, AI has been used
to help in the planning of surgery by constructing three-
dimensional models of renal anatomy from CT scans. [53]
Pattern recognition algorithms have been developed both to
diagnose bladder cancer on cystoscopy, and also stage
urothelial cancer from imaging studies. [54, 55]. To date,
studies have been conducted on small samples, and further
training on larger datasets is needed to improve accuracy to
the level of specialist radiologists, but the results are
encouraging.
Histopathology
The recently developed AI system, Paige Prostate Alpha, is a
detection platform that can be utilised by pathologist to
increase sensitivity of detection of prostate cancer on whole-
slide images from 74% to 90%, with no significant decrease in
specificity [56]. Deep learning systems have also been
developed that can outperform pathologists in the application
of Gleason scores to prostate cancer [57]. Such systems would
work well clinically to screen out benign biopsies and
prioritise high-risk biopsies for assessment by pathologists. AI
has been used for the assessment of percutaneous renal
biopsy to classify RCC subtypes and identify features that
predict survival outcomes, as well as assessing the degree of
kidney disease in biopsy samples [58–60].
Genomics
Advances in genomics may lead to increased precision in the
management of certain cancers. Next-generation sequencing
has been used to profile tumour DNA profiles provide active
sites for targeted therapies [61, 62]. This can be used
concurrently with high throughput screening (HTS). HTS has
led to significant advances in the pharmacology sector [63]. It
makes use of advances in robotics, genetics and data analysis
to test potentially millions of different active reagents or
antibodies to see if they interact with a target providing a
building block in the development of novel therapies. In
American Tumour Board Meetings there have been some
studies showing that it is feasible to look at genomics to
create tailor made cancer treatment regimens to help improve
outcomes [64]. DNA sequences of interest could potentially
be used alongside AI technology, and in the near future.
The Use of Videoconferencing to Improve
Collaborative Decision-Making
Videoconferencing has been controversial in MDTMs, with
apparent advantages and challenges. Regular regional and
even supra-regional MDTMs are not feasible without some
form of remote contact [34]. Technology failure and
differences in communication styles can present challenges to
the quality of MDT decision-making [23, 24]. Perhaps an
ongoing effect of the coronavirus disease 2019 (COVID-19)
pandemic will be the dramatic shift towards telemedicine,
replacing many face-to-face interactions. Many MDTs now
manage to operate remotely via video link. It may be
desirable to supplement this with periodic face-to-face
interaction that permit more nuanced communication
regarding performance, operational policy, challenges, and
future directions [65].
A New Strategy to Involve the Patient
As care pathways in the UK are getting shorter in an attempt
to improve the timeliness of diagnosis and treatment for
patients, patients often have not formally been given a
diagnosis of cancer before their case is reviewed in the
MDTM. Accordingly, when patients’ cases are discussed in
the MDT, data on their attitudes and preferences are
frequently not known, and therefore cannot be incorporated
into care management recommendations. Research suggests
that this makes MDT recommendations less likely to be put
into practice, but in truth little audit or research of the
implementation of MDT outcomes has been published [66].
Researchers have been arguing for better representation of
patients’ interests in MDT decision-making for some time,
but research has consistently shown that patients’ views and
holistic aspects of care are consistently underrepresented [3,
10, 11]. In fact, some researchers have tested the feasibility of
having patients attending MDTMs [67, 68]. Despite the
appeal of this strategy to those who hold strongly to the
principles of patient-centred care, in practice in a system that
is already under strain there might need to be an alternative
way of integrating patients’ interests into MDT decision-
making at scale. One such approach might be to accept the
difficulty in integrating patient-centred information into the
MDTM and to focus instead on the synthesis of a precise
biomedical picture in a streamlined MDTM. An enhanced
post-MDT clinical consultation could then be focussed on
personalising this precise biomedical picture. Resources saved
through streamlined MDTMs could be redirected into the
post-MDTM consultation involving patients, nurses, surgeons,
oncologists and other healthcare professionals in face-to-face
discussions. The result might be the application of a more
precise clinical diagnosis with a personalised care plan for
patients, tailored according to patient preferences,
psychosocial circumstances and comorbidities.
Recommendations and Future Direction
From the present review we can make a number of
recommendations with regards to the future direction of the
MDT:
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• Ensure that sufficient information is presented at the
MDTM for each patient in order to reduce number of
rejected cases or re-discussions.
• Increase utilisation of stakeholder-driven algorithms, such
as the MeDiC screening tool, to triage cases, and aid
streamlining of MDTMs and reduced MDT workload.
• Focus specifically on complex cases during the MDTM.
• MDT Chairs to take on an enhanced role, facilitating
management of urgent cases prior to the MDTM to avoid
delay, with post hoc review of management at the MDTM.
• Gradual implementation of new technologies such as
CDSSs, AI and videoconferencing.
• Enhance post-MDTM out-patient consultations with a
multidisciplinary clinic, using validated decision-making
tools, to support patient decisions and decrease treatment
regret.
• Invest in team development for MDTs (e.g. team
development annual away day), to promote team cohesion
and allow the team to plan how best to run their MDTMs,
how to introduce new technologies and how to enhance
their patient-centredness.
Conclusion
There is little doubt that the delivery of care of patients with
urological cancers is enhanced through the cooperation and
coordination afforded by a multidisciplinary approach. As the
complexity of diagnostic and prognostic information, as well
as treatments increases, this approach will become
increasingly valuable for these patients specifically, and the
health service in general. To allow us to absorb this extra
work, changes will be necessary to streamline the MDT
process and the MDTM in particular. Strategies for
improving and streamlining MDT working have been set out,
which may require enhancement of the post-MDTM
consultation to ensure patients receive holistic care.
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